MDMA (Ecstasy, Molly): Dependence, Comedown, and Recovery Support

MDMA is the drug sold as ecstasy and molly, and most people who take it think of it as a weekend thing rather than something you recover from. Two facts complicate that. First, a capsule sold as molly is often not MDMA: when researchers tested the hair of 48 young New Yorkers who said they had used ecstasy or molly, half tested positive for synthetic cathinones ("bath salts") or other new psychoactive substances (Palamar et al., Drug Alcohol Depend, 2016). Second, it is hard to put down for reasons that have little to do with physical withdrawal. This page covers how a habit forms, the comedown, whether stopping is dangerous, treatment, drug testing, and how ongoing support at home fits.

What MDMA is and how it works

The DEA describes 3,4-methylenedioxymethamphetamine as "a synthetic drug possessing both stimulant and mild hallucinogenic properties" that "is controlled in schedule I of the Controlled Substances Act" (DEA Diversion Control, 2026), the category the DEA defines as "drugs with no currently accepted medical use and a high potential for abuse" (DEA drug scheduling). Street names include "Adam, Beans, Clarity, Disco Biscuit, E, Ecstasy, Eve, Go, Hug Drug, Lover's Speed, MDMA, Molly, Peace, STP, X, and XTC" (DEA fact card, 2026). Ecstasy usually means a pressed tablet; molly means powder or crystal in a gel capsule (DEA fact sheet).

The FDA's review of pharmaceutical MDMA describes the mechanism in one line: it "acts as a serotonin, norepinephrine, and dopamine reuptake inhibitor and releasing agent" (FDA briefing document, 2024). Serotonin is the warmth and the sense that everyone in the room is your friend; norepinephrine and dopamine are the stimulant part: energy, a racing heart, clenched teeth. Effects begin "within 30 to 45 minutes" and last "4 to 6 hours" (DEA); the mean terminal half-life is 8.7 hours (FDA, 2024). The brain does not restock serotonin that fast.

Then there is the question of what is actually in the capsule. The DEA reports that tablets sold as ecstasy often contain "methamphetamine, 3,4-methylenedioxyamphetamine [MDA], ketamine, caffeine, amphetamine, cathinones, synthetic cannabinoids, and/or opioids [e.g., fentanyl]" (DEA). The name molly was meant to signal purity; the New York hair study notes that "Molly is short for 'molecular', as it implies that the product is pure MDMA," yet 47.9 percent of samples contained the cathinone butylone, and 41 percent of people who said they had never knowingly taken such a drug tested positive anyway (Palamar et al., 2016).

Risky use, dependence, and addiction are not the same thing

People use these words interchangeably, and the confusion produces shame that helps no one. MDMA does not produce the physical dependence that opioids or benzodiazepines do. The most thorough review of the question found that "physical features play a more limited role than psychological ones," that "Tolerance is apparent, and withdrawal is self-reported," and that it is unclear whether those reports reflect a "'true' withdrawal syndrome" or the lingering effects of the drug itself (Degenhardt et al., Drug Alcohol Depend, 2010). Where dependence exists, it looks like "compulsive use" and "escalating use."

Risky use is the most common pattern: a few times a year, at festivals or parties, often with alcohol, with the temperature and hydration dangers described below. Tolerance is real; the person who needed one pill now takes three. Addiction, in clinical language a substance use disorder, is continuing despite harm: every weekend, then weeknights, the week organized around the next dose and the recovery from the last one. The FDA's reviewers concluded that "midomafetamine has abuse potential that parallels that of the Schedule II stimulants" such as amphetamine and cocaine (FDA advisory committee presentation, 2024); researchers who favor the drug call addiction "very rare" in medical settings (Sessa et al., Front Psychiatry, 2019). The clinic is not where we meet people.

Signs MDMA has become a problem

The signs members and families describe to us most often look like this. The weekends have gotten longer and closer together. The dose has crept up, with redosing through the night. Monday to Wednesday has become a write-off: exhausted, irritable, tearful. A dentist has asked about worn molars. Sleep is bad even on weeks with no use. Ordinary pleasures have gone gray, and the only thing that feels vivid is the next event. The DEA's list of effects ends with "sleep problems, and drug craving" (DEA). Any one of these is worth a conversation. Several together are worth a call.

Is stopping MDMA dangerous?

Medically, no. Stopping MDMA does not cause the seizures of alcohol or benzodiazepine withdrawal; SAMHSA's stimulant protocol notes that "No consistent physiologic disruptions requiring gradual withdrawal have been observed" (SAMHSA TIP 33, chapter 3). The risk in stopping sits in mood. The same protocol warns that "In the first 1-2 weeks of withdrawal from stimulants, some patients may experience suicidality and should be monitored appropriately," and calls severe, persisting depression in this phase "a major concern" (TIP 33). If someone coming off MDMA talks about not wanting to be here, take it seriously and call or text 988.

The dangerous part of MDMA is using it. The DEA states that "In high doses, MDMA can interfere with the body's ability to regulate temperature," which can end in "liver, kidney, or cardiovascular system failure, swelling of the brain, and even death" (DEA). When the CDC investigated a 2013 electronic music festival in New York City, it found 22 adverse events, of which "nine cases were severe, including two deaths." Toxicology showed "MDMA was identified in one decedent, and MDMA plus methylone (a synthetic cathinone) in the other," and four of the 22 had a body temperature above 102°F (CDC MMWR, 2014). The CDC's summary: MDMA "can cause serious adverse effects, including hyperthermia, seizures, hyponatremia, rhabdomyolysis, and multiorgan failure."

Hyponatremia, low blood sodium, is the other way MDMA kills, and it hits women hardest. MDMA makes the body hold water; people told to hydrate drink liters of it; the brain swells. Of 188 California poison center cases with a documented sodium level, 73 (38.8 percent) were hyponatremic, women made up 75.3 percent of those, and hyponatremic women "demonstrated increased odds of coma" (Rosenson et al., Ann Emerg Med, 2007). Overheating and overhydrating look alike from the inside; a person in either state cannot tell which one they are in.

MDMA comedown and withdrawal timeline

People who use MDMA do not talk about withdrawal. They talk about the comedown, and about "suicide Tuesday." The folklore has some support and some exaggeration. A 2026 diary study of 17 regular users found that "Monday mood was significantly lower following ecstasy-use weekends compared to nonuse weekends," about 1.4 points on a 10-point scale, with much of the drop explained by time spent in bed (Medina-Kirchner and Lukas, Drug Alcohol Depend Rep, 2026). The DEA is blunter: "confusion, anxiety, depression, and paranoia" that "may last weeks after ingestion" (DEA). Everyone differs, and the dose, the sleep lost, and whatever else was in the capsule all change the shape. This is the general pattern we hear.

First 24 hours

The drug wears off and the body presents the bill: exhaustion, a sore jaw, a headache, and sleep that will not come even though you are wrecked. The DEA's "muscle tension, tremors, teeth clenching, nausea, sweating" (DEA) all outlast the euphoria.

Days 2 to 4

This is the low the folklore is about. Serotonin has been spent and not yet remade. Mood drops, small things feel unbearable, and some people feel a flatness that scares them. For someone with an underlying depression this window can be dangerous, which is why we ask about it directly.

Days 5 to 14

Energy and mood usually climb back. For someone using every weekend, this is exactly when the next event arrives, so the low never fully resolves. SAMHSA puts the highest-risk period for suicidality at the first one to two weeks (TIP 33). Cravings attach to cues: a lineup announcement, Friday afternoon.

Weeks 2 and beyond

For someone who has used heavily and often, low mood, poor sleep, and trouble concentrating can run for weeks. The encouraging part: a four-year study of 2,128 Australian adults found that "Ecstasy use was not associated with long-term depressive symptoms" (George et al., Psychopharmacology, 2013). Much of the gray lifts once the cycle breaks.

How treatment works

There is no medication for this. SAMHSA states that "There are no FDA-approved medications for managing stimulant use disorders" (SAMHSA TIP 33, 2021), and nothing specific to MDMA exists either. Contingency management, which rewards verified periods of not using, "is by far the psychosocial treatment with the greatest scientific support," and "After CM, the three other psychosocial interventions with the most support are CBT, community reinforcement, and MI" (TIP 33). In plain terms: a reason to stay sober this week, a way to prove you did, and skills for the moments that used to end in a capsule.

Because it comes up in almost every first conversation: in June 2024 an FDA advisory committee met to "discuss new drug application 215455, for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics" for post-traumatic stress disorder (FDA, 2024). On August 9, 2024, the company announced that the FDA "has issued a complete response letter," declining approval and requesting another Phase 3 trial (Lykos Therapeutics, 2024). The research continues. As of this writing no MDMA product is approved for any use, and a measured dose in a clinic with two therapists present has little in common with a capsule at a festival. One medical piece belongs in every plan: anyone whose crash has included real depression should see a clinician, because the crash sometimes unmasks a depression that predates the drug.

MDMA with alcohol, antidepressants, or other stimulants

Alcohol is the most common companion, and the combination is deceptive. In a controlled study, "The MDMA-alcohol combination induced longer lasting euphoria and well being than MDMA or alcohol alone," yet "MDMA did not reverse the actions of alcohol on psychomotor abilities": people "might have the feeling of doing better, but actual performance ability continues to be impaired" (Hernández-López et al., J Pharmacol Exp Ther, 2002). Plasma MDMA also rose 13 percent with alcohol on board. Add heat, dancing, and the false confidence to drive home.

The antidepressant interaction is the one people do not know about. MDMA releases serotonin; SSRIs, SNRIs, and especially MAO inhibitors keep it around, and too much is serotonin syndrome: agitation, high fever, rigid muscles, sometimes death. MAOI-plus-MDMA has been reported as a cause since 1987 (Sporer, Drug Safety, 1995). A review of the FDA's adverse event database found 20 serotonin syndrome cases in people who had taken MDMA, six also on an SSRI, with deaths among them, and "no cases of SS associated with MDMA where MDMA was the sole reported compound taken" (Makunts et al., Front Psychiatry, 2022). SSRIs also blunt MDMA's effects (Sarparast et al., Psychopharmacology, 2022), which leads some people to take more; the clinical trials excluded anyone on an "SSRI, SNRI, MAOI, or other antidepressant" (FDA). If you take one, your prescriber needs to know about the MDMA.

Other stimulants stack the cardiovascular load. MDMA alone "increases motor activity, alertness, heart rate, and blood pressure" (DEA); methamphetamine, cocaine, or a cathinone does it again, often without the person knowing it was in the capsule. At the New York festival, methylone was found alongside MDMA in 11 of 17 people tested (CDC).

Two smaller harms are worth naming. Teeth: one survey found "89% of the consumers admitted to clenching their teeth," and wear through the enamel "was observed in 60% of ecstasy users, compared to only 11% of non users" (Newell et al., Front Oral Health, 2025; Brand et al., Br Dent J, 2008). Memory: the DEA states that "MDMA may increase the risk of long-term, perhaps permanent, problems with memory and learning" (DEA), and drug-free users in one study "performed worse" in "memory and learning tasks" (Gouzoulis-Mayfrank et al., J Neurol Neurosurg Psychiatry, 2000). The evidence is strongest for heavy use.

Drug testing for MDMA

MDMA is easy to test for. Federal workplace guidelines for oral fluid set an initial cutoff of 50 ng/mL and a confirmatory cutoff of 25 ng/mL for MDMA and MDA (Federal Register, 2019). MDMA-specific saliva windows are not well established; SAMHSA's general guidance is that "drug testing of oral fluids detects drug use during the previous 24-48 hours, regardless of the route of administration" (SAMHSA TAP 32). Redosing and a low lab cutoff push toward the long end, so we would rather not quote one number for everyone.

Our members use saliva-based screening that is assigned at random through the week. MDMA has its own line on the instant 10-panel strip we use, and the lab-confirmed oral fluid test reports MDMA and MDA separately at a 2 ng/mL cutoff, along with methamphetamine and amphetamine for the nights when the capsule was not what it was sold as. You do not choose whether you test; you choose who sees the results, usually your coach and, if you want, a partner or parent. We explain the details in our guide to how sobriety monitoring works.

How recovery from MDMA works with Accountable

We are not a detox and we do not prescribe. What we provide is the behavioral part and the accountability, at home, for as long as you need it.

1. Get the full picture

In the first sessions your coach maps what is actually going on: how often, how much, what the Tuesday after looks like, whether alcohol or cocaine or ketamine ride along, and whether there is an antidepressant in the picture. We ask about the low weeks directly, including thoughts of not being here. With your permission we coordinate with your prescriber or therapist so everyone works from the same plan.

2. Build a plan that fits your life

Most people who come to us for MDMA are not giving up music or their friends, and a plan that requires that is a plan you will abandon. Your coach helps you plan around the real calendar: which events are coming, what you will do at 1 a.m. when the capsule comes around, which friends to tell. Daily peer group meetings and a weekly family Zoom group give the people around you their own support.

3. Weekly check-ins through the long stretch

The hard part of MDMA recovery is week six, when the flatness has lifted and a festival announcement lands in the group chat. Your coach shows up every week, and the saliva screening turns "I think she's doing okay" into a shared record that you control. When a slip happens, we treat it as information: the plan changes and the support goes up. Every coach at Accountable has their own recovery behind them.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

How long does MDMA stay in your system?

The mean terminal half-life is 8.7 hours (FDA, 2024), so most of a single dose is gone within about two days. Oral fluid testing generally detects use "during the previous 24-48 hours" (SAMHSA TAP 32); urine windows are longer.

How long does the MDMA comedown last?

The low usually runs from about day two to day four and eases over the following week. A diary study found Monday mood measurably lower after ecstasy weekends (Medina-Kirchner and Lukas, 2026). Heavy use stretches it; sleep shortens it.

Is MDMA addictive?

It can be, though differently from opioids or alcohol. Tolerance develops and some people use compulsively, but withdrawal is mostly mood and sleep (Degenhardt et al., 2010). The FDA's reviewers concluded its abuse potential "parallels that of the Schedule II stimulants" (FDA, 2024). If it is costing you weeks or relationships and you keep going back, that is what matters.

Is molly the same as MDMA?

It is supposed to be. In practice, half of the ecstasy or molly users in one New York sample had a synthetic cathinone or other new psychoactive substance in their hair (Palamar et al., 2016), and the DEA lists methamphetamine, MDA, ketamine, cathinones, and fentanyl among what turns up in products sold as ecstasy (DEA).

What should I do if someone on MDMA is overheating, confused, or will not wake up?

Call 911. Get them somewhere cool and do not push water; overheating and water intoxication both cause confusion and seizures, and only a hospital can tell them apart (CDC, 2014). Because capsules sold as molly have contained opioids (DEA), if the person is unresponsive and breathing slowly, give naloxone if you have it.

Sources

• Drug Enforcement Administration, Diversion Control Division. MDMA (Ecstasy, Molly, XTC, E, X, Beans, Adams), drug and chemical information sheet, February 2026.

• Drug Enforcement Administration. Ecstasy or MDMA (also known as Molly) drug fact sheet.

• Drug Enforcement Administration. MDMA, Ecstasy and Molly fact card, Get Smart About Drugs, January 2026.

• Drug Enforcement Administration. Drug Scheduling.

• U.S. Food and Drug Administration. FDA Briefing Document, NDA 215455, midomafetamine capsules, Psychopharmacologic Drugs Advisory Committee Meeting. June 4, 2024.

• U.S. Food and Drug Administration. FDA presentations, Psychopharmacologic Drugs Advisory Committee Meeting on midomafetamine capsules (NDA 215455). June 4, 2024.

• U.S. Food and Drug Administration. June 4, 2024: Meeting of the Psychopharmacologic Drugs Advisory Committee, meeting announcement.

• Lykos Therapeutics. Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD. Press release, August 9, 2024.

• Ridpath A, Driver CR, Nolan ML, et al. Illnesses and Deaths Among Persons Attending an Electronic Dance-Music Festival, New York City, 2013. MMWR. 2014;63(50):1195-1198.

• Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR. Patterns of Ecstasy-Associated Hyponatremia in California. Annals of Emergency Medicine. 2007;49(2):164-171.

• Palamar JJ, Salomone A, Vincenti M, Cleland CM. Detection of "Bath Salts" and Other Novel Psychoactive Substances in Hair Samples of Ecstasy/MDMA/"Molly" Users. Drug and Alcohol Dependence. 2016;161:200-205.

• Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug and Alcohol Dependence. 2010;107(1):1-10.

• Medina-Kirchner C, Lukas SE. Monday mood decline after weekend ecstasy use: A retrospective analysis of daily diary reports. Drug and Alcohol Dependence Reports. 2026.

• Sessa B, Higbed L, Nutt D. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Frontiers in Psychiatry. 2019;10:138.

• George AM, Olesen S, Tait RJ. Ecstasy use and depression: A 4-year longitudinal study among an Australian general community sample. Psychopharmacology. 2013.

• Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). Journal of Neurology, Neurosurgery and Psychiatry. 2000;68:719-725.

• Substance Abuse and Mental Health Services Administration. TIP 33: Treatment for Stimulant Use Disorders, Executive Summary. 2021 update, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. TIP 33: Treatment for Stimulant Use Disorders, Chapter 3: Medical Aspects of Stimulant Use Disorders. 2021 update, NCBI Bookshelf.

• Makunts T, Jerome L, Abagyan R, de Boer A. Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database. Frontiers in Psychiatry. 2022;12:824288.

• Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022.

• Sporer KA. The Serotonin Syndrome: Implicated Drugs, Pathophysiology and Management. Drug Safety. 1995;13(2):94-104.

• Hernández-López C, Farré M, Roset PN, et al. 3,4-Methylenedioxymethamphetamine (Ecstasy) and Alcohol Interactions in Humans: Psychomotor Performance, Subjective Effects, and Pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics. 2002;300(1):236-244.

• Newell R, Fouillen K, Orliaguet T, Kichenin M, Boisramé S. Oral health effects of ecstasy (MDMA) and methamphetamine: a narrative review. Frontiers in Oral Health. 2025;6.

• Brand HS, Dun SN, Nieuw Amerongen AV. Ecstasy (MDMA) and oral health. British Dental Journal. 2008;204:77-81.

• Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs, Oral Fluid. Federal Register, 84 FR 57554, October 25, 2019.

• Substance Abuse and Mental Health Services Administration. TAP 32: Clinical Drug Testing in Primary Care. Technical Assistance Publication Series, 2012.